RNA - NASDAQ
Atrium Therapeutics, Inc.
$12.17
-1.3%Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
At a Glance
Live SnapshotAtrium Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Atrium Therapeutics, Inc. Balance Sheet
RNA • NASDAQ
| Atrium Therapeutics, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
270M | 219.9M | 185.1M | 340.4M | 320.4M | 321.5M | 94.6M | 3.1M | |
0.0 | 1.3B | 410.3M | 270.3M | 85.1M | 6.7M | 0.0 | 0.0 | |
270M | 1.5B | 595.4M | 610.7M | 405.5M | 328.1M | 94.6M | 3.1M | |
0.0 | 28.2M | 8.6M | 3.9M | 900K | 1.2M | 0.0 | 0.0 | |
0.0 | 28.2M | 1.1M | 2.4M | 900K | 1.2M | 0.0 | 0.0 | |
0.0 | 0.0 | 7.5M | 1.5M | 0.0 | 0.0 | 0.0 | 0.0 | |
1.5M | 12.6M | 7.3M | 8.3M | 4.7M | 2.3M | 1.1M | 152K | |
1.3M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 152K | |
272.8M | 1.5B | 611.3M | 622.9M | 411.1M | 331.7M | 95.7M | 3.2M | |
NON-CURRENT ASSETS | ||||||||
5.5M | 18.3M | 16.7M | 15M | 15.6M | 1.9M | 631K | 702K | |
0.0 | 3.3M | 596K | 849K | 850K | 298K | 600K | 38K | |
5.5M | 21.6M | 17.2M | 15.9M | 16.4M | 2.2M | 1.2M | 740K | |
278.4M | 1.6B | 628.6M | 638.8M | 427.6M | 333.9M | 96.9M | 4M | |
LIABILITIES | ||||||||
CURRENT LIABILITIES | ||||||||
4.4M | 8.5M | 8.8M | 4.6M | 2.8M | 7.7M | 2.3M | 1.6M | |
4.4M | 8.5M | 8.8M | 4.6M | 2.8M | 7.7M | 2.3M | 1.6M | |
8.9M | 61.1M | 25.5M | 27.9M | 20.2M | 3.2M | 1.3M | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.8M | 2.7M | |
3.7M | 3.8M | 3.6M | 3.1M | 1.8M | 0.0 | 0.0 | 0.0 | |
21.6M | 21M | 28.4M | 5M | 0.0 | 0.0 | 3.8M | 0.0 | |
3.1M | 3.7M | 14.3M | 11.2M | 4.9M | 3.7M | 0.0 | 305K | |
41.8M | 98M | 80.7M | 51.9M | 29.7M | 14.6M | 10.2M | 4.6M | |
NON-CURRENT LIABILITIES | ||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.8M | 7.6M | |
28.7M | 38M | 40.9M | 1.2M | 0.0 | 0.0 | 15.1M | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 134.7M | 0.0 | |
574K | 0.0 | 0.0 | 0.0 | 6.5M | 12.2M | 45K | 32.9M | |
29.3M | 40.9M | 47.1M | 8.8M | 16.5M | 13.1M | 152M | 40.5M | |
3.7M | 6.8M | 9.9M | 10.7M | 11.7M | 938K | 393K | 0.0 | |
71.1M | 138.9M | 127.8M | 60.7M | 46.2M | 27.7M | 162.3M | 45.1M | |
SHAREHOLDERS' EQUITY | ||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 134.7M | 32.7M | |
17K | 12K | 8K | 7K | 5K | 4K | 1K | 426K | |
207.3M | 2.3B | 1.1B | 939.3M | 566.2M | 372.8M | -43.2M | 0.0 | |
0.0 | -893.1M | -570.8M | -358.5M | -184.5M | -66.5M | -22.2M | -41.6M | |
0.0 | 2.9M | 125K | -2.7M | -187K | -5K | -134.7M | -33.1M | |
0.0 | 0.0 | 0.0 | 0.0 | -1.0 | 0.0 | 0.0 | 33.1M | |
207.3M | 1.4B | 500.8M | 578.1M | 381.4M | 306.2M | -65.4M | -41.1M | |
207.3M | 1.4B | 500.8M | 578.1M | 381.4M | 306.2M | -65.4M | -41.1M | |
SUMMARY | ||||||||
278.4M | 1.6B | 628.6M | 638.8M | 427.6M | 333.9M | 96.9M | 4M | |
0.0 | 1.3B | 410.3M | 270.3M | 85.1M | 6.7M | 0.0 | 0.0 | |
3.7M | 6.8M | 9.9M | 10.7M | 11.7M | 938K | 4.9M | 10.3M | |
-266.3M | -213.1M | -175.2M | -329.7M | -308.7M | -320.5M | -89.6M | 7.2M | |
131,245,283 | 131,245,283 | 131,245,283 | 131,245,283 | 131,245,283 | 131,245,283 | 131,245,283 | 131,245,283 |
SEC Filings
RNA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | February 27, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 03, 2026 | February 02, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 14, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 10, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 27, 2025 | October 25, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 14, 2025 | October 13, 2025 | 2025 |
Related Guides
Continue your RNA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.